Payment overview · 2025
General Payments
$753.15
58 reported records · 13 companies
Healthcare provider profile · identity verified
Scott Rappe, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · TYRONE, GA · NPI 1922249267
Verified facts
What the public records show
CMS Open Payments records show Scott Rappe, D.O. received $753.15 in general payments during 2025 across 58 reported records.
ABBVIE INC. accounted for 36.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $275.79 | 36.6% | 34 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $96.00 | 12.8% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.25 | 12.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.22 | 9.3% | 4 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $49.88 | 6.6% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $32.68 | 4.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.41 | 3.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.49 | 3.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.31 | 2.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.68 | 2.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.22 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.04 | 2.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.18 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $753.15 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $254.84 | 32 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $244.14 | 31 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $96.00 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $96.00 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.83 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $71.83 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $49.88 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.61 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.61 | 3 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $32.68 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $32.68 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $29.41 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $10.95 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $10.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 763 | 244 |
| Amlodipine Besylate | Amlodipine Besylate | 725 | 231 |
| Levothyroxine Sodium | Levothyroxine Sodium | 302 | 82 |
| Omeprazole | Omeprazole | 278 | 85 |
| Losartan Potassium | Losartan Potassium | 267 | 82 |
| Lisinopril | Lisinopril | 245 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 84 |
| Metformin Hcl | Metformin Hcl | 206 | 65 |
| Gabapentin | Gabapentin | 193 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 55 |
| Trazodone Hcl | Trazodone Hcl | 142 | 51 |
| Mounjaro | Tirzepatide | 125 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 43 |
| Alprazolam | Alprazolam | 117 | 27 |
| Sertraline Hcl | Sertraline Hcl | 114 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 29 |
| Tramadol Hcl | Tramadol Hcl | 113 | 27 |
| Glipizide | Glipizide | 108 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 43 |
| Potassium Chloride | Potassium Chloride | 104 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 29 |
| Alendronate Sodium | Alendronate Sodium | 84 | 29 |
| Ibuprofen | Ibuprofen | 84 | 33 |
| Ozempic | Semaglutide | 82 | 23 |
| Carvedilol | Carvedilol | 79 | 22 |
| Simvastatin | Simvastatin | 76 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 26 |
| Jardiance | Empagliflozin | 74 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 23 |
| Allopurinol | Allopurinol | 69 | 25 |
| Telmisartan | Telmisartan | 69 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 18 |
| Montelukast Sodium | Montelukast Sodium | 66 | 28 |
| Clonazepam | Clonazepam | 65 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 22 |
| Metformin Hcl Er | Metformin Hcl | 64 | 26 |
| Chlorthalidone | Chlorthalidone | 62 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 15 |
| Donepezil Hcl | Donepezil Hcl | 56 | 13 |
| Furosemide | Furosemide | 56 | 24 |
| Prednisone | Prednisone | 56 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 18 |
| Ondansetron Odt | Ondansetron | 52 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 11 |
| Ezetimibe | Ezetimibe | 51 | 19 |
| Eliquis | Apixaban | 50 | 16 |
| Meloxicam | Meloxicam | 49 | 24 |
| Bupropion Xl | Bupropion Hcl | 46 | 12 |
| Trulicity | Dulaglutide | 44 | 14 |
| Finasteride | Finasteride | 39 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 12 |
| Lorazepam | Lorazepam | 35 | 15 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Estradiol | Estradiol | 34 | 13 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 17 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Naproxen | Naproxen | 23 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Azithromycin | Azithromycin | 22 | 20 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 12 |
| Temazepam | Temazepam | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Lactulose | Lactulose | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $753.15 · 58 records | ABBVIE INC. | AFREZZA, AIRSUPRA, GEMTESA, JARDIANCE, LINZESS, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, UPTRAVI, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error